Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fullcef Plus vs Cefdinir in AECB and CAP
NCT03400735Phase 4Unknown
- Sponsor
- Neutec Group
- Start
- Nov 2017
- Primary completion
- Apr 2018
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of cefdinir, clavulanic acid in chronic bronchitis (CB), community acquired pneumonia (CAP), sponsored by Neutec Group. Status: unknown.
02
Drugs
cefdinirclavulanic acid
03
Conditions
chronic bronchitis (CB)community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT03400735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03400735.